Pfizer and Wisconsin-based diagnostics firm, Exact Sciences, announced an agreement through 2021 to drive a DNA screening test for colorectal cancer through expanded sales and marketing efforts.
The companies will invest a combined $48 million, shared equally, next year to market the non-invasive test, Cologuard. Approved in the United States in 2014 to screen adults aged 50 or older at average risk for colorectal cancer, sales of the diagnostic test jumped 78 percent to nearly $103 million in the latest reported quarter.
Exact Sciences will continue to manufacture the test, with Pfizer chipping in with its sales force to boost marketing.
Read the press release